Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response

BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are innovative small target molecules that, in combination with endocrine therapy, have recently been employed in the treatment of patients with HR(+)/HER2(−) metastatic breast cancer (mBC). In this prospective study, we investigate the im...

Descripción completa

Detalles Bibliográficos
Autores principales: Scirocchi, Fabio, Scagnoli, Simone, Botticelli, Andrea, Di Filippo, Alessandra, Napoletano, Chiara, Zizzari, Ilaria Grazia, Strigari, Lidia, Tomao, Silverio, Cortesi, Enrico, Rughetti, Aurelia, Marchetti, Paolo, Nuti, Marianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061627/
https://www.ncbi.nlm.nih.gov/pubmed/35477069
http://dx.doi.org/10.1016/j.ebiom.2022.104010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061627/
https://www.ncbi.nlm.nih.gov/pubmed/35477069
http://dx.doi.org/10.1016/j.ebiom.2022.104010

Ejemplares similares